Literature DB >> 22639055

Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy.

Fabio Stagno, Paolo Vigneri, Francesco Di Raimondo.   

Abstract

Entities:  

Year:  2012        PMID: 22639055     DOI: 10.1007/s12185-012-1113-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

Authors:  F Guilhot; C Chastang; M Michallet; A Guerci; J L Harousseau; F Maloisel; R Bouabdallah; D Guyotat; N Cheron; F Nicolini; J F Abgrall; J Tanzer
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

2.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Neil P Shah; Andreas Hochhaus; Jorge Cortes; Sandip Shah; Manuel Ayala; Beatriz Moiraghi; Zhixiang Shen; Jiri Mayer; Ricardo Pasquini; Hirohisa Nakamae; Françoise Huguet; Concepción Boqué; Charles Chuah; Eric Bleickardt; M Brigid Bradley-Garelik; Chao Zhu; Ted Szatrowski; David Shapiro; Michele Baccarani
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Authors:  Claude Preudhomme; Joëlle Guilhot; Franck Emmanuel Nicolini; Agnès Guerci-Bresler; Françoise Rigal-Huguet; Frederic Maloisel; Valérie Coiteux; Martine Gardembas; Christian Berthou; Anne Vekhoff; Delphine Rea; Eric Jourdan; Christian Allard; Alain Delmer; Philippe Rousselot; Laurence Legros; Marc Berger; Selim Corm; Gabriel Etienne; Catherine Roche-Lestienne; Virginie Eclache; François-Xavier Mahon; François Guilhot
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

4.  Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.

Authors:  Bengt Simonsson; Tobias Gedde-Dahl; Berit Markevärn; Kari Remes; Jesper Stentoft; Anders Almqvist; Mats Björeman; Max Flogegård; Perttu Koskenvesa; Anders Lindblom; Claes Malm; Satu Mustjoki; Kristina Myhr-Eriksson; Lotta Ohm; Anu Räsänen; Marjatta Sinisalo; Anders Själander; Ulla Strömberg; Ole Weiss Bjerrum; Hans Ehrencrona; Franz Gruber; Veli Kairisto; Karin Olsson; Fredrik Sandin; Arnon Nagler; Johan Lanng Nielsen; Henrik Hjorth-Hansen; Kimmo Porkka
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

5.  Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Authors:  Rüdiger Hehlmann; Michael Lauseker; Susanne Jung-Munkwitz; Armin Leitner; Martin C Müller; Nadine Pletsch; Ulrike Proetel; Claudia Haferlach; Brigitte Schlegelberger; Leopold Balleisen; Mathias Hänel; Markus Pfirrmann; Stefan W Krause; Christoph Nerl; Hans Pralle; Alois Gratwohl; Dieter K Hossfeld; Joerg Hasford; Andreas Hochhaus; Susanne Saussele
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

Review 6.  The renaissance of interferon therapy for the treatment of myeloid malignancies.

Authors:  Jean-Jacques Kiladjian; Ruben A Mesa; Ronald Hoffman
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

7.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

  7 in total
  1 in total

Review 1.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.